Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed ...

Moderna Inc. MRNA shares are trading higher Monday as investors position ahead of detailed Phase 3 melanoma data for its ...

It was a head-turning headline. Here's why the market was buzzing.

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Following last month's super rally, a growing number of analysts are now calling for caution.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran ...

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on ...

One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.

Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares ...

Billionaire biotech mogul Noubar Afeyan has called for urgent regulation of artificial intelligence agents that tech firms ...